Clinical relevance of the cell-free DNA in mesenteric vein blood of colorectal cancer patients.

• Main Authors: Song-Sheng Yang, 楊崧聖
• Other Authors: Chi-Hung Lin
• Format: Others
• Language: en_US
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/02337323706661524048

碩士 === 國立陽明大學 === 微生物及免疫學研究所 === 104 === Colorectal cancer (CRC) is one of the most common cancers in the world and is a significant cause of morbidity and mortality. The cause of CRC mortality is mainly due to resistance to treatment and occurrence of distant metastasis. Reevaluating current knowledge on developing promising CRC treatment response and prognostic biomarkers are therefore crucial. Here, we used liquid biopsies including circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from mesenteric vein blood (MVB) for prognosis assessments. In this study, MVB and peripheral blood (PB) were collected from CRC patients. The percentage of CTCs were examined by Flow cytometry analysis and cfDNA level was quantified by real-time quantitative PCR of ALU repeats and Cysteine-free fragment (CFF), Qubit assay and Pico-Green assay. To investigate the significant role of the CTCs and cfDNA, the clinical parameters and multivariate survival were analyzed in CRC patients. The previous results showed that the CTCs in MVB were more abundant than that in PB. The more CTCs in MVB reveled the poor prognosis. In addition, our results showed the amount of cfDNA was higher in MVB than PB. The cfDNA concentrations were lower in early stage than late stage in MVB. We also found that cfDNA level was inversely correlated with CTCs percentage in the MVB and positively correlated with tumor size. Stage II CRC patients with the higher cfDNA concentrations have the better prognosis (3-year recurrence and disease-free survival rate) than those with the lower cfDNA concentrations. These results indicated that the quantitative levels of cfDNA and CTCs percentage in MVB were more clinical relevance than in PB of CRC patients.